Formulary Monographs [, 682020]
|
|
EMPAGLIFLOZIN|METFORMIN
|
|
|
|
|
|
SODIUM GLUCOSE CO TRANSPORTER INHIBITOR
|
|
|
Indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) when treatment with both empagliflozin and metformin is appropriate
|
|
|
Lactic acidosis is a metabolic complication that can occur due to metformin accumulation during treatment and is fatal in ~50% of cases. Necrotizing fasciitis of the perineum (Fournier gangrene) reported with SGLT2 inhibitors;
|
|
|
Take twice daily with meals (ie, divide total daily dose into 2 doses/day)
For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin. |
|
|
|
|
|
Not recommended during second and third trimester of pregnancy based on animal data
Limited available data with use in pregnant women is not sufficient to determine a drug-associated risk for major birth defects and miscarriages Metformin may result i |
|
|
There is no information regarding presence in human milk, the effects on breastfed infant or on milk production.
Empagliflozin is present in the milk of lactating rats. |
|
|
|